FI3749669T6 - AHR-modulaattoreita - Google Patents
AHR-modulaattoreita Download PDFInfo
- Publication number
- FI3749669T6 FI3749669T6 FIEP19706135.1T FI19706135T FI3749669T6 FI 3749669 T6 FI3749669 T6 FI 3749669T6 FI 19706135 T FI19706135 T FI 19706135T FI 3749669 T6 FI3749669 T6 FI 3749669T6
- Authority
- FI
- Finland
- Prior art keywords
- group
- alkyl
- independently selected
- alkylene
- methyl
- Prior art date
Links
- -1 C1-5-deuteroalkyl Chemical group 0.000 claims 40
- 150000001875 compounds Chemical class 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 229910052736 halogen Inorganic materials 0.000 claims 15
- 150000002367 halogens Chemical class 0.000 claims 15
- 229910052757 nitrogen Inorganic materials 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 13
- 150000002431 hydrogen Chemical class 0.000 claims 11
- 229910052799 carbon Inorganic materials 0.000 claims 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 8
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- 229910052717 sulfur Inorganic materials 0.000 claims 8
- 229910052805 deuterium Inorganic materials 0.000 claims 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 6
- 125000003282 alkyl amino group Chemical group 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 5
- 125000001931 aliphatic group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000004122 cyclic group Chemical group 0.000 claims 4
- 125000001188 haloalkyl group Chemical group 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 3
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 125000002843 carboxylic acid group Chemical group 0.000 claims 3
- 125000005345 deuteroalkyl group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 2
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims 1
- PUTWQCNJUYXTIW-UHFFFAOYSA-N 1-methyl-6-[2-methyl-4-[6-(trifluoromethyl)pyrido[3,2-d]pyrimidin-2-yl]phenyl]-4,5-dihydropyrazolo[3,4-c]pyridin-7-one Chemical compound CN1N=CC2=C1C(=O)N(CC2)C1=C(C)C=C(C=C1)C1=NC=C2N=C(C=CC2=N1)C(F)(F)F PUTWQCNJUYXTIW-UHFFFAOYSA-N 0.000 claims 1
- NOIVWFQNDZCSBZ-UHFFFAOYSA-N 1-methyl-7-[2-methyl-4-[6-(trifluoromethyl)pyrido[3,2-d]pyrimidin-2-yl]phenyl]-5,6-dihydropyrazolo[3,4-f][1,4]oxazepin-8-one Chemical compound CN1N=CC2=C1C(=O)N(CCO2)C1=C(C)C=C(C=C1)C1=NC=C2N=C(C=CC2=N1)C(F)(F)F NOIVWFQNDZCSBZ-UHFFFAOYSA-N 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- NFKJSNDCXKGULS-UHFFFAOYSA-N 7-[2,5-dimethyl-4-[8-methyl-6-(trifluoromethyl)-1,5-naphthyridin-2-yl]phenyl]-1-methyl-5,6-dihydropyrazolo[3,4-f][1,4]oxazepin-8-one Chemical compound CN1N=CC2=C1C(=O)N(CCO2)C1=C(C)C=C(C(C)=C1)C1=CC=C2N=C(C=C(C)C2=N1)C(F)(F)F NFKJSNDCXKGULS-UHFFFAOYSA-N 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Amplifiers (AREA)
- Supplying Of Containers To The Packaging Station (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862626739P | 2018-02-06 | 2018-02-06 | |
| US201962793260P | 2019-01-16 | 2019-01-16 | |
| PCT/US2019/016705 WO2019156987A1 (en) | 2018-02-06 | 2019-02-05 | AhR MODULATORS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FI3749669T3 FI3749669T3 (fi) | 2023-05-26 |
| FI3749669T6 true FI3749669T6 (fi) | 2024-11-13 |
Family
ID=65494575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP19706135.1T FI3749669T6 (fi) | 2018-02-06 | 2019-02-05 | AHR-modulaattoreita |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10815250B2 (enExample) |
| EP (2) | EP4219495A1 (enExample) |
| JP (1) | JP7382348B2 (enExample) |
| CN (1) | CN111683950B (enExample) |
| CA (1) | CA3090150A1 (enExample) |
| DK (1) | DK3749669T6 (enExample) |
| ES (1) | ES2946632T7 (enExample) |
| FI (1) | FI3749669T6 (enExample) |
| TW (1) | TWI840343B (enExample) |
| WO (1) | WO2019156987A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11548867B2 (en) * | 2017-07-19 | 2023-01-10 | Idea Ya Biosciences, Inc. | Amido compounds as AhR modulators |
| JP7382348B2 (ja) | 2018-02-06 | 2023-11-16 | アイディアヤ バイオサイエンシーズ，インコーポレイティド | ＡｈＲモジュレータ |
| AU2020386967A1 (en) * | 2019-11-22 | 2022-07-07 | Sail Biomedicines, Inc. | Pyridopyrimidinone derivatives as AHR antagonists |
| BR112022020965A2 (pt) * | 2020-04-17 | 2022-12-06 | Dong A St Co Ltd | Derivados de piridopirimidinona e seu uso como moduladores de receptores de hidrocarboneto arila |
| US12570638B2 (en) | 2020-05-20 | 2026-03-10 | Sail Biomedicines, Inc. | Fused imidazole derivatives as AHR antagonists |
| CN114181212B (zh) * | 2020-09-15 | 2023-06-06 | 山东轩竹医药科技有限公司 | 哒嗪酮类AhR抑制剂 |
| CN116745622A (zh) * | 2020-10-13 | 2023-09-12 | 先达生物科技公司 | 与免疫检查点抑制剂疗法相关的生物标志物及其使用方法 |
| US20230381182A1 (en) * | 2020-10-13 | 2023-11-30 | Senda Biosciences, Inc. | Biomarkers Related to Immune Checkpoint Inhibitor Therapy and Methods of Using the Same |
| WO2023020512A1 (zh) * | 2021-08-16 | 2023-02-23 | 成都奥睿药业有限公司 | 取代的吡啶类似物、其制备方法及作为ahr调节剂的用途 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU72201A (sh) | 1999-04-28 | 2005-07-19 | Aventis Pharma Deutschland Gmbh. | Derivati di-aril kiseline kao ppar receptorski ligandi |
| JP2005504047A (ja) | 2001-08-13 | 2005-02-10 | チバ スペシャルティ ケミカルズ ホールディング インコーポレーテッド | 紫外線吸収剤 |
| US20050256118A1 (en) | 2004-05-12 | 2005-11-17 | Altenbach Robert J | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
| US7098222B2 (en) | 2004-05-12 | 2006-08-29 | Abbott Laboratories | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
| CR9465A (es) | 2005-03-25 | 2008-06-19 | Surface Logix Inc | Compuestos mejorados farmacocineticamente |
| US8410109B2 (en) | 2005-07-29 | 2013-04-02 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| WO2008054599A2 (en) | 2006-09-27 | 2008-05-08 | Surface Logix, Inc. | Rho kinase inhibitors |
| CA2714181C (en) | 2008-02-04 | 2013-12-24 | Mercury Therapeutics, Inc. | Ampk modulators |
| ES2586459T3 (es) | 2008-05-01 | 2016-10-14 | Glaxosmithkline Llc | Quinolinas y análogos relacionados como moduladores de sirtuina |
| JP2011521958A (ja) * | 2008-05-27 | 2011-07-28 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | Ｗｎｔタンパク質シグナル伝達阻害剤 |
| MX2011009568A (es) | 2009-03-09 | 2011-12-06 | Surface Logix Inc | Inhibidores de la rho cinasa. |
| WO2010148350A1 (en) * | 2009-06-18 | 2010-12-23 | Cornell University | Photoproducts of tryptophan, their synthesis and uses thereof |
| AU2011282776B2 (en) * | 2010-07-27 | 2014-06-12 | Boston Medical Center Corporation | Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics |
| WO2012050500A1 (en) | 2010-10-14 | 2012-04-19 | Lars Pettersson | 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as ahr activators. |
| JP2013545749A (ja) | 2010-11-10 | 2013-12-26 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | 複素環化合物及びその使用 |
| AU2012212323A1 (en) | 2011-02-01 | 2013-09-12 | The Board Of Trustees Of The University Of Illinois | HDAC inhibitors and therapeutic methods using the same |
| EP2788476B1 (en) | 2011-12-08 | 2019-05-22 | Fred Hutchinson Cancer Research Center | Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells |
| MX388871B (es) * | 2014-06-27 | 2025-03-20 | Nogra Pharma Ltd | Moduladores del receptor arilo y metodos para elaborar y usar los mismos. |
| US10669528B2 (en) | 2015-06-25 | 2020-06-02 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance |
| WO2017184547A1 (en) | 2016-04-18 | 2017-10-26 | New York University | Quinoline compounds as modulators of rage activity and uses thereof |
| TWI674260B (zh) | 2017-02-01 | 2019-10-11 | 德商菲尼克斯製藥股份有限公司 | 芳基烴受體(AhR)調節劑化合物 |
| TWI752155B (zh) | 2017-02-01 | 2022-01-11 | 德商菲尼克斯製藥股份有限公司 | 芳香烴受體(AhR)調節劑化合物 |
| TW201835070A (zh) | 2017-02-21 | 2018-10-01 | 德商菲尼克斯製藥股份有限公司 | 芳香烴受體(AhR)調節劑化合物 |
| MX2019012431A (es) | 2017-04-21 | 2020-08-03 | Ikena Oncology Inc | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. |
| US11548867B2 (en) | 2017-07-19 | 2023-01-10 | Idea Ya Biosciences, Inc. | Amido compounds as AhR modulators |
| JP7382348B2 (ja) | 2018-02-06 | 2023-11-16 | アイディアヤ バイオサイエンシーズ，インコーポレイティド | ＡｈＲモジュレータ |
| US20210254006A1 (en) | 2018-06-06 | 2021-08-19 | Ideaya Biosciences, Inc. | Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds |
-
2019
- 2019-02-05 JP JP2020564046A patent/JP7382348B2/ja active Active
- 2019-02-05 EP EP23160174.1A patent/EP4219495A1/en not_active Withdrawn
- 2019-02-05 FI FIEP19706135.1T patent/FI3749669T6/fi active
- 2019-02-05 DK DK19706135.1T patent/DK3749669T6/da active
- 2019-02-05 EP EP19706135.1A patent/EP3749669B3/en active Active
- 2019-02-05 US US16/268,444 patent/US10815250B2/en active Active
- 2019-02-05 CN CN201980011943.5A patent/CN111683950B/zh active Active
- 2019-02-05 WO PCT/US2019/016705 patent/WO2019156987A1/en not_active Ceased
- 2019-02-05 CA CA3090150A patent/CA3090150A1/en active Pending
- 2019-02-05 ES ES19706135T patent/ES2946632T7/es active Active
- 2019-02-11 TW TW108104425A patent/TWI840343B/zh active
-
2020
- 2020-09-17 US US17/023,980 patent/US11407764B2/en active Active
-
2022
- 2022-06-29 US US17/853,647 patent/US12258354B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3090150A1 (en) | 2019-08-15 |
| JP2021512954A (ja) | 2021-05-20 |
| DK3749669T3 (da) | 2023-06-06 |
| US20230039955A1 (en) | 2023-02-09 |
| EP3749669B1 (en) | 2023-03-08 |
| TW201945362A (zh) | 2019-12-01 |
| US11407764B2 (en) | 2022-08-09 |
| WO2019156987A1 (en) | 2019-08-15 |
| DK3749669T6 (da) | 2024-11-18 |
| EP3749669B3 (en) | 2024-09-04 |
| ES2946632T3 (es) | 2023-07-21 |
| FI3749669T3 (fi) | 2023-05-26 |
| EP4219495A1 (en) | 2023-08-02 |
| US12258354B2 (en) | 2025-03-25 |
| JP7382348B2 (ja) | 2023-11-16 |
| US20210002297A1 (en) | 2021-01-07 |
| CN111683950B (zh) | 2024-04-16 |
| EP3749669A1 (en) | 2020-12-16 |
| TWI840343B (zh) | 2024-05-01 |
| CN111683950A (zh) | 2020-09-18 |
| US20190270754A1 (en) | 2019-09-05 |
| US10815250B2 (en) | 2020-10-27 |
| ES2946632T7 (es) | 2025-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3749669T6 (fi) | AHR-modulaattoreita | |
| KR101156230B1 (ko) | 융합된 헤테로사이클 화합물 | |
| AU2011234398B8 (en) | Novel NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | |
| CA2499134C (en) | Fused azole-pyrimidine derivatives | |
| AP762A (en) | Substituted 6,5-hetero-bicyclic derivatives. | |
| JP4049207B2 (ja) | 抗真菌活性を有する新規ピリミドン誘導体 | |
| ES2620612T3 (es) | Derivados de sulfóxidos y sulfonas de piridinilo y pirimidinilo | |
| JP2015511245A5 (enExample) | ||
| IL100864A0 (en) | Benzimidazole compounds,their preparation and pharmaceutical compositions containing them | |
| FI4074703T3 (fi) | Pyridinyyli-(atsa)indolsulfonamiidit | |
| KR102346508B1 (ko) | 키나제 억제제로서 유용한 치환된 테트라히드로카르바졸 및 카르바졸 카르복스아미드 화합물 | |
| TN2018000295A1 (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors | |
| AU2014369153A1 (en) | Nrf2 regulators | |
| WO2008088692A3 (en) | Spirochromanon derivatives | |
| JP2017503867A5 (enExample) | ||
| UA76461C2 (en) | Pyrrazole derivatives as pharmaceutical agents, use thereof, a pharmaceutical composition on their basis | |
| KR20140069209A (ko) | 신규의 바이러스 복제 저해제 | |
| HUE029366T2 (en) | Bicyclic-substituted uracil derivatives and their use | |
| IL268080A (en) | Compounds that modulate the Caryl Hydrogen receptor | |
| WO2003024441A1 (en) | Novel use of tricyclic compound | |
| EP1812450A2 (en) | Tgf-beta inhibitors | |
| RU2013136542A (ru) | Конденсированные производные аминодигидротиазина | |
| TWI295671B (en) | Tricyclic tetrahydroquinoline antibacterial agents | |
| ATE360004T1 (de) | Imidazopyridine, -pyrimidine und -triazine als gaba-a alpha 5 rezeptor subtyp liganden zur verbesserung kognitiver eigenschaften | |
| JP2021512954A5 (enExample) |